17 May 2016
Craven House Capital plc ("Craven House" or the "Company")
Cash placing of 277,411,748 new ordinary shares at 1.25 pence per share
Craven House Capital (AIM: CRV) announces that it has raised approximately £3.47 million in cash (before expenses), through a placing (the "Placing") of 277,411,748 new ordinary shares of 0.1p each in the Company ("Placing Shares") at a price of 1.25p per Placing Share ("Placing Price").
The net proceeds of the Placing will be used to further execute the Company's investment policy. A number of prospective investment opportunities in our target markets are currently under evaluation and further updates will be provided to the market in due course.
Further to previous announcements, the Company is continuing its discussions with additional prospective investors with regard to making investments in the Company via further subscriptions for new shares and updates will be provided to the market in due course.
Application will be made for the Placing Shares, which will rank pari passu with the existing ordinary shares in the Company, to be admitted to trading on AIM. It is expected that Admission will become effective and dealings will commence at 8.00 a.m. on 23 May 2016.
Following Admission the total issued share capital will consist of 1,082,952,620 ordinary shares. As such the total number of voting rights in the Company will be 1,082,952,620 ordinary shares. This number may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.
~ Ends ~
For further information please contact:
Craven House Capital Plc Mark Pajak
|
Tel: 020 7002 1027
|
SI Capital Broker Nick Emerson |
Tel: 01483 413500 |
SPARK Advisory Partners Limited Nominated Adviser Matt Davis/Mark Brady |
Tel: 0203 368 3550
|
About Craven House Capital
Craven House Capital (AIM: CRV) is an investment company seeking deep value opportunities across the globe. It seeks to create long-term shareholder value on a per share basis by deploying patient capital. Craven House seeks to acquire real assets and operating companies that capable of generating steady cash flows.